Biosceptre was founded in 2003, on science from the University of Sydney, Australia. With a UK headquartered Oncology Biotech with staff in Cambridge UK and Sydney Australia.
Biosceptre has identified a new oncology target – nfP2X7 present on the majority of cancers and expressed in at least 50% of all tumours.
Biosceptre has therapies that exploit this target in the clinical stage, and a significant IP portfolio and expertise associated with nfP2X7. Biosceptre has world class scientific leadership and collaborations with Key Opinion Leaders and major research institutes that expand our science and augment our therapeutic pipeline.
Successful exploitation of nfP2X7 in cancer has the potential to generate equity value measured in the billions and to deliver real improvement to cancer outcomes for millions of people.
|Aim of funding
|HMRC Advanced Assurance received
|Envisaged investor exit
|IPO or Trade Sale
|In excess of 10x Capital Invested